- AGC Biologics has partnered with Pyramid Pharma Services to expand its US fill-finish offering, combining drug substance development and manufacturing with sterile drug product services.
- The collaboration will provide integrated manufacturing and packaging options, including prefilled syringes, cartridges, and liquid and lyophilized vials, supporting programs from clinical development through commercial production.
AGC Biologics, a contract development and manufacturing organization (CDMO), has partnered with Pyramid Pharma Services to expand its fill-finish capabilities for US clients. The collaboration combines AGC Biologics’ drug substance development and manufacturing services with Pyramid’s fill-finish operations, providing an integrated supply chain option for biopharmaceutical developers. The partnership is effective immediately, with the companies ready to begin initial projects.
The offering will cover prefilled syringes, cartridges, and liquid and lyophilized vials, supporting programs from clinical development through commercial-scale manufacturing. Pyramid will provide device assembly, labeling and secondary packaging from its GMP facility in Costa Mesa, California.
The partnership is intended to reduce supply chain complexity and the number of handoffs between manufacturing providers. Clients can choose how closely they participate in project management. AGC Biologics’ project management teams can oversee subcontracting activities, including shipments, production slot allocations and technical coordination, or involve clients directly in project activities.
The collaboration follows a similar model to AGC Biologics’ European partnership with BioConnection, which provides fill-finish services in that region. AGC Biologics said the US-based option will support developers seeking domestic end-to-end production, combining its mammalian and microbial manufacturing capabilities with Pyramid’s sterile dose delivery services.
AGC Biologics said demand for an all-US supply chain accelerated the partnership, which had already been planned. The companies aim to provide a more integrated manufacturing pathway for customers developing products for the US market.